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USE OF PARTHENOLIDE DERIVATIVES AS
ANTILEUKEMIC AND CYTOTOXIC AGENTS

ment as a therapeutic agent. Thus, a need exists for the devel

opment of soluble parthenolide derivatives that retain their

anti-cancer activity.
This is a divisional application of US. patent application
Ser. No. 11/031,315 ?led Jan. 7, 2005, now US. Pat. No.
7,678,904, Which is a continuation-in-part of US. patent
application Ser. No. 10/888,274 ?led Jul. 9, 2004, now US.
Pat. No. 7,312,242, Which claims the bene?t of priority to

SUMMARY OF THE INVENTION

In accordance With the present invention, a novel class of

compounds With antileukemic activity is presented. Accord
ingly, the present invention provides compounds of formula

provisional application No. 60/486,171 ?led Jul. 11, 2003.

(I):

FIELD OF THE INVENTION

(1)

The present invention relates to methods for the structural

modi?cation of the sesquiterpene lactone, parthenolide, and
the use of these parthenolide derivatives in the treatment of
carcinoma. More speci?cally, the invention relates to the
methods to prepare structural analogs of the parent com

R6

pound, parthenolide, in order to obtain neW, pharmacologi
cally active chemical entities With improved Water solubility

R5

Z

20

characteristics, and to use them in the treatment of leukemias

and other parental and multi-drug resistant cancers
BACKGROUND OF THE INVENTION

Wherein:
25

X1, X2 and X3 are heteroatoms;
R4, R5, R6, R7, R8, R9 and R10 are independently selected
from H, halo, ‘OH, iNOZ, 4CN and optionally substi
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; and

30

Z is optionally substituted C L8 straight-chained or branched
aliphatic, optionally containing 1 or more double or triple
bonds, Wherein one or more carbons are optionally replaced

Sesquiterpene lactones are a group of secondary plant
metabolites consisting of a 15-carbon structure containing an

ot-methylene-y-butyrolactone moiety and other additional
functional groups. Over the last tWo to three decades, these
terpenoids have received considerable attention due to the

broad spectrum of their biological activities, to the plants
Which produce them, and most importantly, because of their
pharmacological effects in humans. About 4,000 of these

by R* Wherein R* is optionally substituted cycloalkyl, het
erocycloalkyl, aryl or heteroaryl; an amino acid residue, H,

terpenoids have been isolated and identi?ed, most of them in

Asteraceae (Compositae, sun?ower family) (Schmidt, Curr
Org. Chem. 1999, 3, 577-608). Some of these plants have

35

been used for centuries in indigenous medical practices in
various cultures WorldWide.
Parthenolide (1) is a Germacrane sesquiterpene lactone
With a unique structure. It has been isolated from several

iSOzNRli, iNRlR2, or iNRISOZi, wherein R1 and
40

R2 are independently selected from H and optionally substi

tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; or Where R* is NRIRZ, R1 and R2 optionally together

different species in Asteraceae (Compositae) family, fever
feW (Tanacetum parthenium) being one of them.
45

With the nitrogen atom form an optionally substituted 5-12
membered ring, said ring optionally comprising 1 or more
heteroatoms and/or a group selected from iCOi, iSOi,
iSOZi and iPOi; or
a pharmaceutically acceptable salt, ester or prodrug
thereof.

The invention also provides a pharmaceutical composition
50

comprising an effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, ester or prodrug

thereof, in combination With a pharmaceutically acceptable
diluent or carrier.

The invention also provides a method of inhibiting cancer

FeverfeW has been used to reduce fever and pain and in the
treatment of mi graine and rheumatoid arthritis (Heptinstall et

55

istering to a mammal afflicted with cancer, an amount of a

al., ACS Symposium Series (1998), 691 (Phytomedicines of
Europe), 158-175.). The active component is parthenolide
(1). Recently, it has been revealed that parthenolide (1) can
induce tumor apoptosis by the inhibition of NF-KB activities

compound of formula (I), effective to inhibit the groWth of
said cancer cells.
60

(Cory et al., Anticancer Research 2002, 22, 3805-9; Cory et
al., Anticancer Research 2001, 21, 3807-11; Gelfanov et al.,
Blood, 2000, 98, 2508-17; Kang et al, Brit. J. Pharmacol.
2002, 135, 1235-44; Song et al., .1. Asian. Nat. Prod. Res.

2001, 3, 285-91).
Parthenolide (1) is a lipophilic, neutral lactone With loW

polarity, and has a loW Water-solubility, limiting its develop

cell groWth and metastasis of cancer cells, comprising admin

The invention also provides a method comprising inhibit
ing cancer cell groWth by contacting said cancer cell in vitro
or in vivo With an amount of a compound of formula (I),
effective to inhibit the groWth of said cancer cell.

65

The invention also provides a compound of formula (I) for
use in medical therapy (preferably for use in treating cancer,
e.g. solid tumors), as Well as the use of such compound for the
manufacture of a medicament useful for the treatment of
cancer and other diseases/ disorders described herein.

US 8,124,652 B2
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4

The invention further provides methods of treating in?am
matory diseases and disorders, including, for example, rheu
matoid arthritis, osteoarthritis, allergies (such as asthma), and
other in?ammatory conditions, such as pain (such as

such combinations result in stable compounds. In addition,
unless otherWise indicated, functional group radicals are

independently selected. Where “optionally substituted”
modi?es a series of groups separated by commas (e. g.,
“optionally substituted A, B or C”; or “A, B or C optionally
substituted With”), it is intended that each of the groups (e. g.,

migraine), swelling, fever, psoriasis, in?ammatory boWel dis
ease, gastrointestinal ulcers, cardiovascular conditions,
including ischemic heart disease and atherosclerosis, partial
brain damage caused by stroke, skin conditions (eczema,
sunburn, acne), leukotriene-mediated in?ammatory diseases

A, B and C) is optionally substituted.
The term “aliphatic” or “aliphatic group” as used herein
means a straight-chain or branched C H 2 hydrocarbon chain
that is completely saturated or that contains one or more units

of lungs, kidneys, gastrointestinal tract, skin, prostatitis and

paradontosis.

of unsaturation, or a monocyclic C3_8 hydrocarbon orbicyclic

The invention further provides methods of treating
immune response disorders, Whereby the immune response is
inappropriate, excessive or lacking. Such disorders include

C8_l2 hydrocarbon that is completely saturated or that con
tains one or more units of unsaturation, but Which is not

allergic responses, transplant rejection, blood transfusion

“cycloalkyl”), that has a single point of attachment to the rest
of the molecule Wherein any individual ring in said bicyclic

aromatic (also referred to herein as “carbocycle” or

reaction, and autoimmune disorders such as systemic lupus
erythematosus and rheumatoid arthritis.

ring system has 3-7 members. For example, suitable aliphatic
groups include, but are not limited to, linear or branched or

BRIEF DESCRIPTION OF THE DRAWINGS
20

FIG. 1 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against prostate cancer cell line
CWR22 in a clonogenic assay.
FIG. 2 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
A-549 in a cellular proliferation MTS-PMS assay.
FIG. 3 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-522 in a cellular proliferation MTS-PMS assay.
FIG. 4 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-23 in a cellular proliferation MTS-PMS assay.
FIG. 5 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-460 in a cellular proliferation MTS-PMS assay.
FIG. 6 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
HBL-lOO in a clonogenic assay.
FIG. 7 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
MD-23l in a clonogenic assay.
FIG. 8 shoWs the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
MD-436 in a clonogenic assay
FIG. 9 shoWs parthenolide and DMAPT plasma concen

enyl.
The terms “alkyl,” “alkoxy,” “hydroxyalkyl,” “alkoxy
alkyl” and “alkoxycarbonyl,” used alone or as part of a larger

moiety include both straight and branched chains containing
25

The terms “haloalkyl,” “haloalkenyl” and “haloalkoxy”
30

means alkyl, alkenyl or alkoxy, as the case may be, substituted
With one or more halogen atoms. The term “halogen” or

“halo” means F, Cl, Br or I.
The term “heteroatom” means nitrogen, oxygen, or sulfur
35

and includes any oxidiZed form of nitrogen and sulfur, and the
quatemiZed form of any basic nitrogen. Heteroatom further
includes Se, Si and P.
The term “aryl” used alone or in combination With other

terms, refers to monocyclic, bicyclic or tricyclic carbocyclic
ring systems having a total of ?ve to fourteen ring members,
40

45

Wherein at least one ring in the system is aromatic and
Wherein each ring in the system contains 3 to 8 ring members.
The term “aryl” may be used interchangeably With the term
“aryl ring”. The term “aralkyl” refers to an alkyl group sub
stituted by an aryl. The term “aralkoxy” refers to an alkoxy
group substituted by an aryl.

The term “heterocycloalkyl,” “heterocycle,” “heterocy
clyl” or “heterocyclic” as used herein means monocyclic,

bicyclic or tricyclic ring systems having ?ve to fourteen ring
members in Which one or more ring members is a heteroatom,
50

FIG. 11 shoWs FSCScan analysis of TRAIL induced apo
ptosis assay using MDA-MB-23l breast cancer cells treated

Wherein each ring in the system contains 3 to 7 ring members
and is non-aromatic.
The term “heteroaryl,” used alone or in combination With

other terms, refers to monocyclic, bicyclic and tricyclic ring

?rst With DMAPT, then TRAIL-RII-activating antibodies.
FIG. 12 shoWs FSCScan analysis of TRAIL induced apo
ptosis assay using MDA-MB-23l breast cancer cells treated
?rst With DMAPT, then TRAIL.

one to tWelve carbon atoms. The terms “alkenyl” and “alky
nyl” used alone or as part of a larger moiety shall include both
straight and branched chains containing tWo to tWelve carbon
atoms.

trations at one hour folloWing oral gavage in mice.
FIG. 10 shoWs DMAPT dose-dependent inhibition of NF
kB DNA binding in tWo transitional cell carcinoma cell lines

HT-l376 and UMUC-3 in electrophoretic mobility gel shift
assay (EMSA).

alkyl, alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alk

55

systems having a total of ?ve to fourteen ring members, and
Wherein: l) at least one ring in the system is aromatic; 2) at
least one ring in the system contains one or more heteroatoms;

and 3) each ring in the system contains 3 to 7 ring members.
The term “heteroaryl” may be used interchangeably With the

DETAILED DESCRIPTION OF THE INVENTION

term “heteroaryl ring” or the term “heteroaromatic”.

As used herein, the folloWing de?nitions shall apply unless

60

otherWise indicated.

The phrase “optionally substituted” is used interchange
ably With the phrase “substituted or unsubstituted.” Unless
otherWise indicated, an optionally substituted group may
have a substituent at each substitutable position of the group,
and each substitution is independent of any other. Also, com
binations of substituents or variables are permissible only if

65

Examples of heteroaryl rings include 2-furanyl, 3-furanyl,

N-imidaZolyl, 2-imidaZolyl, 4-imidaZolyl, 5-imidaZolyl,
3-isoxaZolyl, 4-isoxaZolyl, 5-isoxaZolyl, 2-oxadiaZolyl,
5-oxadiaZolyl, 2-oxaZolyl, 4-oxaZolyl, 5-oxaZolyl, l-pyrro
lyl, 2-pyrrolyl, 3-pyrrolyl, l-pyraZolyl, 3-pyraZolyl, 4-pyra
Zolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrim
idyl, 5-pyrimidyl, 3-pyridaZinyl, 2-thiaZolyl, 4-thiaZolyl,
5-thiaZolyl, 5-tetraZolyl, 2-triaZolyl, 5-triaZolyl, 2-thienyl,

US 8,124,652 B2
6

5
3-thienyl, carbaZolyl, benZimidaZolyl, benZothienyl, benZo
furanyl, indolyl, quinolinyl, benZotriaZolyl, benZothiaZolyl,
benZooxaZolyl, benZimidaZolyl, isoquinolinyl, indaZolyl,

4CO2H, iCOZ (C l_4 aliphatic), iO(halo C1_4 aliphatic) or
-halo(Cl_4 aliphatic); Wherein each Cl_4 aliphatic is option
ally substituted.

isoindolyl, acridinyl, and benZoisoxaZolyl. The term “het

The term “linker group” or “linker” means an organic

eroaralkyl” refers to an alkyl group substituted by a het
eroaryl. The term “heteroarylalkoxy” refers to an alkoxy
group substituted by a heteroaryl. \

moiety that connects tWo parts of a compound. Linkers
include alkylidene chain that is a saturated or unsaturated,

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the
like) or heteroaryl (including heteroaralkyl, heteroarylalkoxy

substituted, and Wherein up to tWo non-adjacent saturated
carbons of the chain are optionally replaced by R* Wherein

and the like) group may contain one or more substituents.

R* is 4C(O)i, 4C(O)C(O)i, iC(O)NRi, 4C(O)
NRNRi, 4C(O)Oi, iOC(O)i, iNRCOzi, 40*,

straight or branched, C1_8 carbon chain Which is optionally

Suitable substituents on an unsaturated carbon atom of an

aryl, heteroaryl, aralkyl or heteroaralkylgroup are selected

iNRC(O)NRi, iOC(O)NRi, iNRNRi, iNRC
(O)i, iSi, iSOi, iSOZi, iNRi, iSOZNRi, or

from halogen; haloalkyl; ‘C133; iR; iOR; iSR; 1,2
methylenedioxy; l,2-ethylenedioxy; protected OH (such as
acyloxy); phenyl (Ph); Ph substituted With R; 4O(Ph);
iOi(Ph) substituted With R; ‘CH2 (Ph); iCHZ (Ph) sub
stituted With R; 4CH2CH2 (Ph); 4CH2CH2 (Ph) substituted

iNRSO2i; Wherein R is selected from hydrogen or option

ally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl
or heteroaryl, and preferably H or optionally substituted C l_4
aliphatic. Optional substituents on the alkylidene chain are as

With R; iNOZ; iCN; *N(R)2; *NRC(O)R; iNRC(O)N

(R)2; iNRCOzR; *NRNRC(O)R; iNRiNRC(O)N(R)2;
iNRNRCOzR; 4C(O)C(O)R; iC(O)CH2C(O)R;
*COZR; *C(O)R; %(O)N(R)2; *OC(O)N(R)2;
*S(O)2R; *SOZNGOZ; *S(O)R; *NRSOZMR»;
*NRSOZR;
%(:S)N(R)2;
*C(:NH)*N(R)2;

i(CH2)y NHC(O)R; i(CH2)yR; i(CH2)yNHC(O)NHR;
i(CH2)yNHC(O)OR;
i(CH2)yNHS(O)R;

20
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iO(Ph), or ‘CH2 (Ph)4CH2 (Ph), Wherein y is 0-6; Z is
0-1; andV is a linker group. When R is Cl_6 aliphatic, it may

The term “therapeutically effective amount” refers to that

35

An aliphatic group or a non-aromatic heterocyclic ring
may contain one or more substituents. Suitable substituents 40
on a saturated carbon of an aliphatic group or of a non

aromatic heterocyclic ring are selected from those listed
above for the unsaturated carbon of an aryl or heteroaryl
45

(alkyl), or :NR, Where each R is independently selected
from hydrogen or an optionally substituted Cl_6 aliphatic.
more substituents selected from iNH2, iNH(Cl_4 ali
50

iO(halo C1_4 aliphatic), or -halo(Cl_4 aliphatic); Wherein
each C1_4 aliphatic is optionally substituted.

iP(:O)(OH)i, is replaced With a pharmaceutically
acceptable cation (eg a sodium, potassium, or ammonium
ion) and can be conveniently be prepared from a correspond
ing compound of formula (I) by, for example, reaction With a
administration of the compounds as salts may be appropriate.

55

Examples of pharmaceutically acceptable salts are organic
acid addition salts formed With acids that form a physiologi

iC(:NH)iN(R)2 or iNRSOZR; Wherein each R is inde

pendently selected from hydrogen, an optionally substituted
optionally substituted 4CH2CH2 (Ph), or an unsubstituted
5-6 membered heteroaryl or heterocyclic ring. When R is a
C1_6 aliphatic group or a phenyl ring, it may be substituted

example, mono-salts (e.g. alkali metal and ammonium salts)
and poly salts (e.g. di- or tri-salts,) of the compounds of the
invention. Pharmaceutically acceptable salts of compounds
of formulas (I), (II), (III), or (IV) are Where, for example, an

suitable base. In cases Where compounds are suf?ciently
basic or acidic to form stable nontoxic acid or base salts,

iR, iN(R)2, iC(O)R, iC(O)OR, 4C(O)C(O)R,
iC(O)CH2C(O)R, iSOZR, iSO2N(R)2, 4C(:S)N(R)2,
C1_6 aliphatic, optionally substituted phenyl (Ph), optionally
substituted iO(Ph), optionally substituted iCH2 (Ph),

The term “pharmaceutically acceptable salts” includes, but

exchangeable group, such as hydrogen in iOH, iNHi, or

When R is C1_6 aliphatic, it may be substituted With one or

Substituents on a nitrogen of a non-aromatic heterocyclic
ring are selected from

severity of the disease condition, the manner of administra
tion and the like, Which can readily be determined by one of
ordinary skill in the art.
is not limited to, salts Well knoWn to those skilled in the art, for

group and the following: :0, :S, :NNHR, :NN(R)2,

phatic), iN(C1_4 aliphatic)2, halogen, 40H, iOi(Cl_4
aliphatic), iNOZ, 4CN, 4CO2H, ‘CO2 (C1_4 aliphatic),

mammal in need of such treatment. The therapeutically effec
tive amount Will vary depending upon the subject and disease

condition being treated, the Weight and age of the subject, the

iCOZ (C1_4 aliphatic), iO(halo Cl_4 aliphatic), or -halo
(C l_4 aliphatic); Wherein each C1_4 aliphatic is optionally.

:Ni, :NNHC(O)R, :NNHCO2 (alkyl), :NNHSO2

tion; or (iv) relieving the conditions mediated by the patho
logic condition.
amount of a compound of the invention that is su?icient to
effect treatment, as de?ned above, When administered to a

be substituted With one or more substituents selected from

iNHZ, iNH(Cl_4 aliphatic), iN(C1_4 aliphatic)2, iS(O)
(Cl_4 aliphatic), iSO2 (Cl_4 aliphatic), halogen, (Cl_4 ali
phatic), 40H, 4O(C1_4 aliphatic), iNOZ, 4CN, 4CO2H,

logic condition in a mammal, particularly a human, and
includes: (i) preventing the pathologic condition from occur
ring in a subject Which may be predisposed to the condition
but has not yet been diagnosed With the condition and, accord
ingly, the treatment constitutes prophylactic treatment for the

disease condition; (ii) inhibiting the pathologic condition,
i.e., arresting its development; (iii) relieving the pathologic
condition, i.e., causing regression of the pathologic condi

i(CH2)yNHSO2R; or i(CH2)yNHC(O)CH((V)ZiR)(R)
Wherein each R is independently selected from hydrogen,
optionally substituted Cl_6 aliphatic, an unsubstituted 5-6

membered heteroaryl or heterocyclic ring, phenyl (Ph),

described above for an aliphatic group. Alternatively, the
linker group is R*.
The term “treatment” refers to any treatment of a patho
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cal acceptable anion, for example, tosylate, methane
sulfonate, acetate, citrate, malonate, tartarate, succinate, ben
Zoate, ascorbate, ot-ketoglutarate, and ot-glycerophosphate.
Suitable inorganic salts may also be formed, including hydro
chloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts include quaternary
ammonium salts formed With R'Y; Where Y is selected from

halogen, tosylate, methanesulfonate, benZenesulfonate, trif

With one or more substituents selected from iNHZ, iNH 65 luoromethanesulfonate and the like; and R' is selected from

(Cl_4 aliphatic), iN(C1_4 aliphatic)2, halogen, i(Cl_4 ali
phatic), 40H, 4Oi(Cl_4 aliphatic), iNOZ, 4CN,

an optionally substituted cycloalkyl, heterocycloalkyl, aryl or

heteroaryl.
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Suitable acids include hydro?uoric acid, hydrochloric
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric
acid, phosphoric acid, carbonic acid, boric acid, selenious

Antiviral Chem & Chemo. 12: 293-300; Knaggs et al., 2000
Bioorganic & Med. Chem. Letters 10: 2075-2078) each of

Which is incorporated in their entirety herein by reference.
The invention relates to the ability of the ot-methylene-y
butyrolactone moiety in sesquiterpene lactones to be struc
turally modi?ed by, for example, Michael addition With

acid, hydrogen sul?de, phosphomolybdic acid, phosphorous
acid, sulfurous acid, citric acid, maleic acid, D-malic acid,
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, meth
anesulfonic acid, valeric acid, oleic acid, lauric acid, para

amines or thiols. Modi?cation of the parthenolide (1) mol

toluenesulfonic acid, l-naphthalensulfonic acid, 2-naphtha

ecule by this methodology using primary and/or secondary

lensulfonic acid, phthalic acid, tartaric acid, L-malic acid,
DL-malic acid, malonic acid, succinic acid, fumaric acid,

amines to form Water-soluble amino derivatives, affords
amine adducts that can easily be obtained as different inor
ganic or organic salts to further increase Water solubility.

glycolic acid, thioglycolic acid, glycine, sarcocine, sulfonic
acid, nicotinic acid, picolinic acid, isonicotinic acid, benZoic

Thus, a novel class of more Water-soluble parthenolide ana

acid and substituted benZoic acid Where benZene ring bears

logs is described. When compounds in this class Were evalu

one or more substituents.

ated for antileukemic activity, it Was found that these com
pounds Were either equipotent as, or more potent than the

Pharmaceutically acceptable salts may be obtained using
standard procedures Well knoWn in the art, for example, by

parent compound, parthenolide. More importantly, these

reacting a suf?ciently basic compound such as an amine With
a suitable acid affording a physiologically acceptable anion.

Alkali metal (for example, sodium, potassium or lithium) or
alkaline earth metal (for example, calcium) salts of carboxy

novel analogs shoWed greater cytotoxicity toWards leukemia
20

lic acids can also be made.

The term “prodrug” or “prodrugs” is used in its ordinary

vided compounds of formula (I):

meaning in the art and means a compound of the invention

that has its charged moieties masked or protected by another
moiety that is designed to be cleaved under particular physi

cells than toWards normal cells. Thus, the present invention
provides a neW class of parthenolide derivatives With potent
and selective anticancer activities.
In accordance With the present invention, there are pro

25

(I)

ological conditions, leaving the deprotected or unmasked
compound of the invention. The use of masking agents is
common and Well-knoWn in the art and, in particular, masking
phosphate or phosphonate groups. All such masking agents
are suitable and can be used With the compounds of the
invention. Various agents such as acyloxy alkyl esters are

30

described by Srivasta et al., (1984 Bioorganic Chemistry 12,
118-12), and by Freeman et al. (1997 Progress in Medicinal
Chemistry 34:112-147) Which are each incorporated in their

entirety herein by reference; and 3-phthalidyl phosphonate
esters are described by Dang Q, et al., (1999 Bioorganic &
Med. Chem. Letters, 9:1505-1510), Which is incorporated in
its entirety herein by reference. For example, and not by Way
of limitation, Srivasta et al. also describe acetoxymethyl,
isobutryloxymethyl, and pivaloxymethyl as masking agents.

35

Wherein:

40

Other suitable masking groups comprising pivaloxyalkyl,
e.g., pivaloxymethyl, or a pivaloyloxy group as described by

Farquhar D. et al., (1995 .1. Med. Chem., 38:488-495) Which
is incorporated in its entirety herein by reference. Still other
masking or protecting agents are described in US. Pat. Nos.
4,816,570 and 4,968,788 both of Which are incorporated in

45

X1, X2 and X3 are heteroatoms;
R4, R5, R6, R7, R8, R9 and R10 are independently selected
from H, halo, 40H, iNO2, 4CN and optionally substi
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; and
Z is optionally substituted C1_8 straight-chained or
branched aliphatic, optionally containing 1 or more double or
triple bonds, Wherein one or more carbons are optionally

replaced by R* Wherein R* is optionally substituted
cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino

their entirety herein by reference. Lipid prodrugs are also
suitable for use With the compounds of the invention. By

acid residue, H, 4CN, iC(O)i, iC(O)C(O)i, 4C(O)

non-limiting example, certain lipid prodrugs are described in
Hostetler et al., (1997 Biochem. Pharm. 53:1815-1822), and

NRli, iC(O)NR1NR2i, %(o)oi, wc(o)i,
iNRICOZi, 40*, iNR1C(O)NR2i, iOC(O)NRli,
iNRINRZi, iNRlC(O)i, isi, isoi, isozi,

50

Hostetler et al., 1996 Antiviral Research 31:59-67), both of
Which are incorporated in their entirety herein by reference.

iNRli, iSOZNRIi, iNRlRz, or iNRlsOzi,

Additional examples of suitable prodrug technology is
described in WO 90/00555; WO 96/39831; WO
03/095665A2; US. Pat. Nos. 5,411,947; 5,463,092; 6,312,
662; 6,716,825; and US. Published Patent Application Nos.
2003/0229225 and 2003/0225277 each of Which is incorpo
rated in their entirety herein by reference. Such prodrugs may
also possess the ability to target the drug compound to a
particular tissue Within the patient, e.g., liver, as described by

wherein R1 and R2 are independently selected from H and

optionally substituted aliphatic, cycloalkyl, heterocycloalkyl,
55

stituted 5-12 membered ring, said ring optionally comprising
1 or more heteroatoms and/ or a group selected from 4COi,
60

prodrugs suitable foruse With the compounds of the invention
are described in WO 03/090690; and by Harris et al., (2002

iSOi, iSOZi and iPOi; or
a pharmaceutically acceptable salt, ester or prodrug
thereof.

Erion et al., (2004 J. Am. Chem. Soc. 126:5154-5163; Erion et
al., Am. Soc. Pharm. & Exper The}: DOI:10.1124/
jept.104.75903 (2004); WO 01/18013 A1; US. Pat. No.

6,752,981), each of Which is incorporated in their entirety
herein by reference. By Way of non-limiting example, other

aryl or heteroaryl; or Where R* is NRlR2, R1 and R2 option
ally together With the nitrogen atom form an optionally sub

Presently preferred compounds include compounds of for
mula (I) wherein R5, R6, R7, R9 and R10 are independently
selected from H, halo, ‘OH, iNOZ, iCN, iCH3, ‘C133,
65

%H2CH3, iCH2CF3, iCHzCl, %H2OH, %H2CH2
OH and iCHZNHZ. Further preferred embodiments include
compounds Where R5, R6, R7, R9 and R10 are each H.
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l l S, l 1,13 -Dihydro, l 3-(homopiperidin-l -yl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(heptamethyleneimin-l -yl)partheno

Other preferred embodiments of the present invention
include compounds Where R4 and R5 are independently
selected from optionally substituted Cl-C4 alkyl. In one pre

lide;
1 18,1 1,13 -Dihydro, l 3-(aZetidin-l -yl)parthenolide;

ferred embodiment, R4 is ‘CH3, and in another, R4 and R8

l l S, l l , l 3 -Dihydro, l 3-methylbutylaminoparthenolide;

are each ‘CH3.
In one embodiment X1, X2 and X3 are heteroatoms inde

1 18,1 1,13 -Dihydro, l 3-methyl pentylaminoparthenolide;
1 18,1 1,13 -Dihydro, l 3-ethylaminoparthenolide;

pendently selected from O, N and S, and in one particular
embodiment, X1, X2 and X3 are each 0.
According to one embodiment, it is preferred that Where

l l S, l 1,13 -Dihydro, l 3-methylaminoparthenolide;
l l S, l 1,13 -Dihydro, l 3-cyclopropylaminoparthenolide;
1 18,1 1,13 -Dihydro, l 3-propargylaminoparthenolide;
l l S, l 1,13 -Dihydro, l 3-(N-benZyl-N-ethylamine)partheno

R5, R6, R7, R9 and R10 are H, R4 and R5 are each iCH3, and
X1, X2 and X3 are each 0; Z is not :CH2.

lide;

According to a further embodiment of the invention, Z is
i(CH2)miNR1R2 Where m is an integer from 0 to 4, Where

1 18,1 1,13 -Dihydro, l 3-(N-prolyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(S -thiophenolyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(N,N-diethanolamine)parthenolide
l l S, l 1,13 -Dihydro, l 3-(thiomorpholin-4 -yl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(4 -hydroxypiperidin- l -yl)partheno

preferably, R5, R6, R7, R9, and R10 are H; and R4 and R5 are
each ‘CH3. In one particular embodiment, m is 1. In other

embodiments, R1 and R2 are independently selected from
hydrogen, 4CN or optionally substituted C l-C4 alkyl. In
particular embodiments, R1 and R2 are independently

lide;
l l S, l 1,13 -Dihydro, l 3-(1 -methylhomopiperiZin-4 -yl)par

selected from iNOZ, 4CN, ‘CH3, iCF3, iCH2CH3,

iCH2CF3, iCHzCl, iCHzOH, iCHzCHzOH and
iCHZNHZ.
In yet a further embodiment, R1 and R2 together With N
form an optionally substituted ring. The ring is a monocyclic,
bicyclic or tricyclic aliphatic or aryl ring system, Where the
ring system is optionally substituted and optionally com

thenolide;
20

parthenolide;
1 18,1 1,13 -Dihydro, l 3-(piperaZin-l -yl-4-carboxaldehyde)

parthenolide;
1 18,1 1,13 -Dihydro, l 3-(4 -benZylpiperidin- l -yl)partheno

prises one or more heteroatoms or a group selected from

iCOi, iSOi, iSOZi and iPOi. In one particular
embodiment, R1 and R2 are iCHZ (CH2)nCH2Yi, WhereY

25

lide;
1 18,1 1,13 -Dihydro, l 3-(piperidin-l -yl-4-carboxylic

parthenolide;

is a heteroatom or a group selected from 4COi, iSOi,

iSOZi and iPOi; n is an integer 0 to 5; and together With
N form an optionally substituted ring, Which may be addi
tionally fused to a cycloalkyl or aryl group to form a bicyclic

l l S, l 1,13 -Dihydro, l 3-(S -mercaptoacetyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(4-(2'-hydroxyethyl)piperidin-l -yl)

30

or tricyclic ring system, Where the system is optionally sub
stituted and optionally comprises one or more heteroatoms.

Alternatively, R1 and R2 are i(CH2)aiYi(CH2)bi,

acid)

1 18,1 1,13 -Dihydro, l 3-(aZetidin-l -yl-3 -carboxylic acid)par
thenolide;
1 18,1 1,13 -Dihydro, l 3-(S-cysteinyl)parthenolide;
1 18,1 1,13 -Dihydro, l 3-(4-(piperidin- l '-yl)piperidin- l -yl))
parthenolide; and
1 18,1 1,13 -Dihydro, l 3-diallylaminoparthenolide.

Where Y is a heteroatom or a group selected from 4COi,

Those of skill in the art Will recogniZe that the invention

iSOi, iSOZi and iPOi; a is an integer 0 to 5; b is an
integer 0 to 5; Where the sum of a and b is 0 to 5; and together

comprises compounds that may contain one or more chiral

35

centers on, for example, the parthenolide C-ll and thus can

With N form an optionally substituted ring, the ring being

exist as racemic mixtures as pure diastereomers, or as pure

optionally fused to a cycloalkyl or aryl group to form a bicy

enantiomers. For many applications, it is preferred to carry
out stereoselective synthesis and/or to subject the reaction
product to appropriate puri?cation steps so as to produce
substantially stereochemically pure or optically pure materi

clic or tricyclic ring system, Where the system is optionally
substituted and optionally compries one or more heteroat
oms.

40

als. Suitable stereoselective synthetic procedures for produc

Examples of ring systems include an optionally substituted
uracil ring or a derivative thereof. Other examples include

ing stereochemically pure or optically pure materials are Well
knoWn in the art, as are procedures for resolving racemic
mixtures into their optically pure enantiomers.

optionally substitute pyrrole, imidaZole, purine and pyraZole
and derivative thereof. Examples of fused ring systems

include optionally substituted aZiridin-l-yl, aZetidin-l-yl,
pyrrolidin- l -yl, piperidin-l -yl, homopiperidyn- l -yl and hep
tamethyleneimin- l -yl.

45

Wherein Z is a group that is converted to :CH2 under physi

According to a further embodiment of the invention, Z is
i(CH2)miS(O)niR1 Where m is an integer from 0 to 4, n is

ological conditions during or after administration to a mam

an integer from 0 to 2, Where preferably, R5, R6, R7, R9, and
R10 are H; and R4 and R5 are each ‘CH3. In one particular

The present invention further provides for compounds hav
ing formula (I), or a pharmaceutically acceptable salt thereof,

50

malian patient, thereby yielding a methylene group. In par
ticular embodiments X1, X2 and X3 are 0; R5, R6, R7, R9, and
R10 are H; R4 and R5 are ‘CH3; and Z is optionally substi

embodiment, m is 1.
In another embodiment n is 0. In other embodiments, R1 is

tuted C L8 straight-chained or branched aliphatic, optionally

independently selected from hydrogen, iCN, optionally

more carbons are optionally replaced by R* Wherein R* is

substituted C 1 -C4 alkyl or aryl. In particular embodiments, R1
is selected from 4C6H5, 4CH2CH(CO2H)(NH2), and

containing 1 or more double or triple bonds, Wherein one or

55

%(O)C(O)i, %(O)NRli, %(O)NRlNR2i, %(O)
of, ioc(o)i, iNRICOZi, ioi, iNR1C(O)
NRL, A)C(O)NRli, iNRINRZi, iNR1C(O)i,

iCH2CO2H.

Exemplary compounds of the present invention include:

1 l S, l l , l 3 -Dihydro, l 3 -dimethylaminoparthenolide

isi, isoi, isozi, iNRli, iSOZNRIi,

(DMAPT);
l l S, l l , l 3-Dihydro, l 3-diethylaminoparthenolide;
l l S, l l , l 3-Dihydro, l 3-(tert-butylamino)parthenolide;
l l S, l l , l 3-Dihydro, l 3-(pyrrolidin-l -yl)parthenolide;

iNRlRz, or iNRISOZi, wherein R1 and R2 are indepen
dently selected from H and optionally substituted aliphatic,

cycloalkyl, heterocycloalkyl, aryl or heteroaryl. In preferred
embodiments Z is iCH2N(CH3)2, 4CH2N(H)(C(CH3)3),

l l S, l l , l 3-Dihydro, l 3-(piperidin-l -yl)parthenolide (PIPT);
l l S, l 1,13 -Dihydro, l 3 -(morpholin- l -yl)parthenolide;
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperidin-l -yl)partheno

lide (4MEPT);
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperaZin-l -yl)partheno

lide;

optionally substituted cycloalkyl, heterocycloalkyl, aryl or
heteroaryl; an amino acid residue, H, 4CN, 4C(O)i,

65

%H2N(CH2CH3)2, iCH2N(CH2CH:CH2)2, %H2
aZetidine, iCHz-pyrrolidine, iCHZ-piperidine, 4CH2-ho
mopiperidine, 4CH2-heptamethyleneimine, iCH2-4-me
thylpiperidine, 4CH2-morpholine, iCHz-pyrrolidine,
4CH2-proline, 4CH2-thiophenol, 4CH2-diethanolamine,

US 8,124,652 B2
11
iCH2-hydroxypiperidine, ‘CH2-methylhomopiperaZine,
iCH2-thiomorpholine, iCH2-mercaptoacetic acid,
iCHz-benzylpiperidine, ‘CH2-piperidine-4-carboxylic
acid, ‘CH2-aZetidine-3-carboxylic acid, 4CH2-piperidi

12
-continued

nylpiperidine, or iCHZ-cysteine.
The present invention further provides for compounds hav
ing formula (I), or a pharmaceutically acceptable salt thereof,
Wherein Z is CH2N(CH3)2 Which under physiological condi
tions during or after administration to a mammalian patient,
undergoes mono- or di-demethylation; conversion to :CH2,

or cysteine or protein conjugation. In particular embodi

S cheme II

ments, X1, X2 and X3 are 0; R5, R6, R7, R9, and R10 are H; R4
and R8 are iCH3;

The present invention further provides compounds
Wherein the parthenolide based derivatives of formula (I)
form dimers or duplexes With another molecule of formula (I)
or With basic nitrogen-containing synergistic anticancer drug
molecules such as 5-?uorouracil, cytarabine, mytomycin C,
Doxorubicin and Daunorubicin. Accordingly, the present

R3NH2

invention provides compounds of the general formula (IDUI)
solvent,

base temperature

25
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Where L is a linker, as de?ned above, and W is a molecule

With anti-cancer groWth activity. Where W is another par
thenolide derivative of formula (I), the present invention pro
vides compounds of formula (III):
(In)

35

In the above scheme, the solvent is selected from a loW alkyl
40

alcohol, such as methanol, ethanol, propanol, isopropanol,

n-butanol, tert-butanol, and chloroform, methylene chloride,
benZene, toluene, tetrahydrofuran, dioxane, 1,2-dimethoxy
ethane, pyridine, carbon tetrachloride, diethyl ether, tert-bu
tyl methyl ether and/or the mixture of tWo or more of the
solvents listed above. The base is selected from a loW trialky
45

Where R'4, R's, R'6, R'7, R's, R'9, R'lo, X'l, X‘2 and X'3 are
independently as de?ned above for their counterparts, R6, R7,
R8, R9, R10, X1, X2 and X3; and L is a linker, as de?ned above.
Preferred linkers include optionally substituted alkyl and
amine groups. In one particular embodiment, L is iCHzN

50

lamine, such as trimethylamine, triethylamine, tripropy
lamine, and tributylamine, and pyridine, 2-, 3-, and 4-pi
colines, 2-, 3-, and 4-dimethylaminopyridines. The
temperature is selected from —200 C. to 130° C. The reaction
time required to effect the desired coupling reaction can vary
Widely, typically falling in the range of 30 min to 24 hours.
Puri?cation can be achieved by a variety of techniques, such

as, liquid chromatography through neutral or basic silica gel,
bonded silica gel phases such as octadecylsilica, octylsilica

(R)CH2i, Where R is as de?ned above. Included are phar

maceutically acceptable salts formed With inorganic and/or
organic acids, as de?ned above for compounds of formula (I).

and the like, cellulose or alumina With the solvent such as, for
example, the mixture of chloroform and methanol or ethanol,
the mixture of methylene chloride and methanol or ethanol,

In accordance With another embodiment of the invention,
the methods for the preparation of the amino analogs
described in this inventionirle dislclosed in Schemes I and II.

the mixture of hexane and acetone or acetonitrile or methanol

or ethanol or isopropanol, the mixture of diethyl ether and
acetone or acetonitrile or methanol or ethanol or isopropanol;

and recrystallization using normal organic solvent or solvent
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mixture, such as methanol, ethanol, propanol, isopropanol,

tert-butanol, acetonitrile, diethyl ether, chloroform, methyl
ene chloride and the mixture of tWo or more solvents listed

HNRIRZ
solvent,

above. The purity of the invention compounds prepared is

—>

assessed by mass spectrometry, nuclear magnetic resonance

base temperature

spectrometry (NMR) and elemental combustion analysis.
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Furthermore, in accordance With still another embodiment
of the present invention, the methods for the preparation of
the invention salts are disclosed in Schemes III and IV.

